CRISPR Therapeutics AG (CRSP): Price and Financial Metrics


CRISPR Therapeutics AG (CRSP)

Today's Latest Price: $188.49 USD

3.39 (1.83%)

Updated Jan 22 4:00pm

Add CRSP to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

CRSP Stock Summary

  • CRSP's price/sales ratio is 169.04; that's higher than the P/S ratio of 97.39% of US stocks.
  • Over the past twelve months, CRSP has reported earnings growth of 1,884.94%, putting it ahead of 99.41% of US stocks in our set.
  • As for revenue growth, note that CRSP's revenue has grown -63.62% over the past 12 months; that beats the revenue growth of only 3.14% of US companies in our set.
  • Stocks that are quantitatively similar to CRSP, based on their financial statements, market capitalization, and price volatility, are ARGX, DNLI, ZYME, MEIP, and ARVN.
  • CRSP's SEC filings can be seen here. And to visit CRISPR Therapeutics AG's official web site, go to www.crisprtx.com.

CRSP Stock Price Chart Interactive Chart >

Price chart for CRSP

CRSP Price/Volume Stats

Current price $188.49 52-week high $220.20
Prev. close $185.10 52-week low $32.30
Day low $182.25 Volume 1,794,700
Day high $190.03 Avg. volume 2,651,643
50-day MA $149.98 Dividend yield N/A
200-day MA $96.70 Market Cap 13.42B

CRISPR Therapeutics AG (CRSP) Company Bio


CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The company is based in Basel, Switzerland.


CRSP Latest News Stream


Event/Time News Detail
Loading, please wait...

CRSP Latest Social Stream


Loading social stream, please wait...

View Full CRSP Social Stream

Latest CRSP News From Around the Web

Below are the latest news stories about CRISPR Therapeutics AG that investors may wish to consider to help them evaluate CRSP as an investment opportunity.

ARK ETFs Might Be Too Popular for Their Own Good

ARK Investment has attracted many investors, thanks to its focus on innovative companies. But it now owns too much of some companies, which could limit its ability to select and trade stocks freely.

Yahoo | January 21, 2021

The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics

The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics

Yahoo | January 20, 2021

CRISPR (CRSP) Up More Than 80% in Past 3 Months: Here's Why

CRISPR Therapeutics' (CRSP) lead gene-editing candidate CTX001, being developed for treating SCD and TDT, holds potential. It has a strong partner in Vertex.

Yahoo | January 19, 2021

Editas (EDIT) Up More Than 100% in Past 3 Months: Here's Why

Editas' (EDIT) lead candidate EDIT-101, that employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating SCD.

Yahoo | January 18, 2021

7 CRISPR Stocks for the Future of Medicine

In June 2012, the world changed forever. You probably didn’t even notice. It was in that month’s issue of the Science journal that U.C. Berkeley professor Jennifer Doudna and Umea University professor Emmanuelle Charpentier unveiled what the scientific community has since labeled the “scientific breakthrough of the century.” The breakthrough: CRISPR-Cas9 genetic editing systems.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Doudna and Charpentier invented a pair of “scissors” – called CRISPR-Cas9 systems – to cut specific DNA threads and modify genes inside of living organisms. How? Bacteria. Doudna and Charpentier noted a naturally occurring genome editing system in bacteria, wherein bacteria capture snippets of DNA from invading viruses and create new DNA segments call...

Yahoo | January 15, 2021

Read More 'CRSP' Stories Here

CRSP Price Returns

1-mo 8.81%
3-mo 103.44%
6-mo 108.62%
1-year 233.20%
3-year 386.05%
5-year N/A
YTD 23.11%
2020 151.39%
2019 113.18%
2018 21.68%
2017 15.89%
2016 N/A

Continue Researching CRSP

Here are a few links from around the web to help you further your research on CRISPR Therapeutics AG's stock as an investment opportunity:

CRISPR Therapeutics AG (CRSP) Stock Price | Nasdaq
CRISPR Therapeutics AG (CRSP) Stock Quote, History and News - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8642 seconds.